Objectif
The XANA project aims at developing a user-friendly wearable device and ICT solution for the customized treatment of stress. We will provide an innovative and non-invasive technology of stimulation of the vagus nerve and a range of integrated services such as feedback on performance, monitoring and access to professional counselling when needed.
Stress is suffered by over 26% of working population. The European Commission estimated in 2002 the cost of work-related stress at €20 billion a year just in the EU-15. Of this, direct costs are mostly paid by the public healthcare systems, and indirect costs are related to productivity loss, ultimately impacting national economies.
Current alternatives do not fully solve the challenge of stress treatment, because of their limited efficacy and presence of secondary effects (invasive electrical stimulation or pharmacological treatment). Moreover, the treatment results are very variable, time consuming (psychological techniques) and expensive. XANA main benefits are: avoidance of secondary effects, high efficacy, user-friendliness, fast and customized treatment providing actual physiological activity. XANA will contribute to the development of mobile Health in Europe. In this, the ICT characteristics of the product are key to possibly enabling burden-reduction in healthcare systems through real-time treatment optimisation and remote medical monitoring/counselling.
XANA project is led by the Spanish start-up Walden Medical®. XANA has a clear potential for becoming an international benchmark in the field of mental health. We have estimated that after 5 years from launch, we will build around 69.700 devices (sales €28M), hire 12 technical employees and manage 0.1% of the world market. We will earn around €10M profit and generate a R.O.I of 6.90. Investment in the XANA product will furthermore ease commercialization of Walden Medical® technologies for other high prevalence conditions: anxiety and migraine.
Champ scientifique
- natural sciencesbiological sciencesneurobiology
- medical and health sciencesclinical medicinepsychiatry
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
- medical and health sciencesbasic medicinephysiologyhomeostasis
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
33203 GIJON
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.